Peter Lange
Director/Board Member bij Technical University of Berlin
Profiel
Peter Lange is currently the Vice Chairman at the Technical University of Berlin and a Member-Supervisory Board at Vakzine Projekt Management GmbH since 2012.
He previously worked as a Lecturer at Eberhard Karls Universität Tübingen in 1994.
Dr. Lange has an undergraduate degree from the University of Gottingen and a doctorate degree from Eberhard Karls Universität Tübingen.
Actieve functies van Peter Lange
| Bedrijven | Functie | Begin |
|---|---|---|
Vakzine Projekt Management GmbH
 Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | Corporate Officer/Principal | - |
| Technical University of Berlin | Director/Board Member | 16-11-2009 |
Eerdere bekende functies van Peter Lange
| Bedrijven | Functie | Einde |
|---|---|---|
| Eberhard Karls Universität Tübingen | Corporate Officer/Principal | 01-01-1994 |
Opleiding van Peter Lange
| University of Gottingen | Undergraduate Degree |
| Eberhard Karls Universität Tübingen | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
Vakzine Projekt Management GmbH
Vakzine Projekt Management GmbH Pharmaceuticals: MajorHealth Technology Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany. | Health Technology |
